PROCEPT BioRobotics Corporation Announces Board Expansion and Appointment of Daniel Puckett as Director

San Jose, CA, March 5, 2026 – PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”; NASDAQ: PRCT), a leading developer of innovative robotic surgical solutions, announced a significant change to its Board of Directors, as disclosed in its latest Form 8-K filing with the Securities and Exchange Commission.

Key Developments in the Report

• Expansion of Board Size: The Board of Directors has approved an increase in its size from eight to nine members.
• Appointment of New Director: Daniel Puckett has been appointed as the newest member of the Board, filling the resulting vacancy.
• Audit Committee Appointment: Mr. Puckett has also been named to the Audit Committee of the Board, effective immediately.

Potentially Price-Sensitive Information for Shareholders

• Independence and Qualifications:
  
  The Board has determined that Mr. Puckett qualifies as an “independent director” under relevant SEC and Nasdaq rules. This ensures continued strong oversight and governance, particularly on the Audit Committee, which is vital for financial transparency and regulatory compliance.
• Director Classification and Term:
  
  Mr. Puckett is classified as a Class III director. His initial term will expire at the Company’s 2027 annual meeting of stockholders and will continue until his successor is elected and qualified, or until his earlier death, resignation, or removal.
• Relevant Experience:
  
  Mr. Puckett brings extensive financial and operational leadership experience in the medical device and diagnostics industries, including having served as Chief Financial Officer at Shockwave Medical, Inc. (April 2016 – February 2024), Counsyl, Inc. (June 2015 – April 2016), and Ariosa Diagnostics, Inc. (2011 – June 2015). His expertise is expected to add significant value to the Board, especially in guiding the company through potential growth, strategic investments, and compliance processes.
• Compensation and Governance:
  
  Mr. Puckett will be compensated in line with other non-employee directors, as per the Company’s Non-Employee Director Compensation Program and the details set out in the Company’s April 25, 2025 proxy statement. He will also enter into the standard director and officer indemnification and advancement agreement.
• No Related Party Transactions or Arrangements:
  
  There are no arrangements or understandings between Mr. Puckett and any other persons regarding his appointment, nor are there any reportable related party transactions under Item 404(a) of Regulation S-K.

Strategic and Shareholder Implications

The appointment of Daniel Puckett is noteworthy for several reasons:

• Strengthening of Financial Oversight: Mr. Puckett’s significant experience as a CFO in the medtech sector is likely to enhance the Company’s financial strategy, audit processes, and risk management. This could increase investor confidence in PROCEPT’s governance and operational discipline.
• Signals Growth and Maturity: Expanding the Board and adding a highly experienced independent director often signals a company preparing for further growth, new initiatives, or enhanced regulatory scrutiny—developments that can be material to share value.
• Market Sensitivity: Changes in board composition, especially with high-profile or experienced directors, can be viewed positively by the market, potentially impacting stock price in the short and medium term.

About Daniel Puckett

• Education: M.B.A. from the University of San Francisco; B.A. in Accounting from Washington State University.
• Professional Background: Extensive leadership roles in finance and operations at Shockwave Medical, Counsyl, Ariosa Diagnostics, Forest Laboratories, Cerexa, Affymetrix, and AOL.

Other Disclosures

• There are no amendments to previously filed or accepted submissions, as indicated by the “Amendment Flag” being set to false.
• No written communications, soliciting materials, or pre-commencement tender offers were reported as part of this Form 8-K filing.

Conclusion

The expansion of the Board of Directors and the addition of Daniel Puckett, a seasoned financial executive with a strong medtech background, is a significant development for PROCEPT BioRobotics Corporation. Shareholders should monitor future communications for any strategic initiatives or financial outcomes stemming from this strengthened governance structure.

Disclaimer: This article is based on information disclosed in PROCEPT BioRobotics Corporation’s Form 8-K filed on March 5, 2026. It is intended for informational purposes only and does not constitute investment advice, an offer, or solicitation for the purchase or sale of any securities. Investors should perform their own due diligence and consult with professional advisors before making investment decisions. The author and publisher assume no liability for the use of this information.

View PROCEPT BioRobotics Corp Historical chart here